Minicircle DNA-Engineered CAR T Cells Suppressed Tumor Growth in Mice.
Viral-based CAR T cell manufacturing has potential safety risks and relatively high costs. The non-viral minicircle DNA (mcDNA) is safer for patients, cheaper to produce, and may be a more suitable technique to generate CAR T cells. In this study, we produced mcDNA-based CAR T cells specifically targeting PSCA (mcDNA-PSCA-CAR T cells). Our results showed that mcDNA-PSCA-CAR T cells persisted in mouse peripheral blood as long as 28 days and demonstrated more CAR T cell infiltration, higher cytokine secretion levels, and better anti-tumor effects. Together, our results suggest that mcDNA-CAR can be a safe and cost-effective platform to produce CAR T cells.